Results 181 to 190 of about 142,029 (216)

Distinct Symptom Occurrence Subgroups Among Patients With Colorectal Cancer: Differences in Social Determinants of Health and Diet Quality

open access: yesResearch in Nursing &Health, EarlyView.
ABSTRACT Colorectal cancer (CRC) is a leading cause of cancer mortality in the United States. Many patients with CRC experience physical and psychological symptoms that diminish quality of life and are shaped by social determinants of health (SDOH) and diet quality.
Youran Lee   +18 more
wiley   +1 more source

Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions

open access: yesPrecision Radiation Oncology, EarlyView.
Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu   +4 more
wiley   +1 more source

Experience with hinotori<sup>TM</sup>, the Japan-made Surgical Robotic System, in the Initial 94 Cases of Colorectal Cancer. [PDF]

open access: yesJ Anus Rectum Colon
Yamamoto T   +11 more
europepmc   +1 more source

A new perspective on radiotherapy in the comprehensive treatment of cancer

open access: yesPrecision Radiation Oncology, EarlyView.
Radiotherapy remains a key component in the comprehensive management of cancer. Its effectiveness is significantly improved through strategic combinations with chemotherapy, targeted therapy, and immunotherapy, providing a range of therapeutic outcomes from cure to palliative care.
Yingze Ma   +4 more
wiley   +1 more source

Real‐World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4–10 ng/mL

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Prostate‐specific antigen (PSA) is a widely used prostate cancer marker; however, its use is limited by its low specificity. Novel biomarkers are being explored to avoid unnecessary biopsies. A new prostate cancer marker, S2,3PSA, became eligible for insurance coverage in February 2024.
Jun Furumido   +10 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

open access: yesPhytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee   +9 more
wiley   +1 more source

Laparoscopic Rectopexy for Neorectal Prolapse after Robot-Assisted Intersphincteric Resection for Low Rectal Cancer: A Case Report. [PDF]

open access: yesSurg Case Rep
Harada Y   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy